Pre-Emptive Strike With Bortezomib (VELCADE) in Participants With Multiple Myeloma Still Event-Free on Total Therapy 2 (UARK 98-026).
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 Mar 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 15 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 May 2008 New trial record.